ClinicalTrials.gg
RecruitingNCT05184582Neo-ACTUpdated Sep 22, 2025

Physical Exercise During Preoperative Chemotherapy for Breast Cancer

An interventional study of Physical training in Breast Cancer, sponsored by Karolinska Institutet. Recruiting at 13 sites in 4 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
712
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in Breast Neoplasms by Karolinska Institutet — 4 open to participants now, 6 under way, 2 of them phase 3. Breast Neoplasms · Karolinska Institutet.

Planned enrollment
6th of 18
712 · median 175
Started
2022
with 2 others
No phase
13 of 19
2 open now
Registered
13th of 19
by date

Among the 19 studies in Breast Neoplasms by Karolinska Institutet, this one is the 6th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2022, is one of 13 with no phase, and was the 13th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 19 studies in Breast Neoplasms by Karolinska Institutet are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Breast Neoplasms by Karolinska Institutet, or all of them as a file.
02

Study summary

Neoadjuvant chemotherapy (NACT) is increasingly used in breast cancer. The best proof of NACT efficacy is pathological complete response (pCR), i.e. the absence of invasive tumour on post-NACT surgical histopathology. While it is known that physical exercise can help patients to better tolerate and complete often harsh cancer treatments, it is an emerging area of research to understand if and how exercise exerts anti-tumour effects and improves oncological outcomes.

The main aim of the Neo-ACT trial is to examine if a physical exercise intervention during NACT can increase pCR rates in breast cancer. Secondary aims are residual cancer burden, radiological tumour response, patient-related outcomes (health-related quality of life, physical activity), physiological outcomes (muscle strength, cardiorespiratory fitness), cancer treatment-related toxicities (cognitive dysfunction, chemotherapy completion rates) and long-term sick leave. Furthermore, the trial will explore how physical exercise affects anti-tumoral mechanisms inherent to therapy or host by hypothesis-generating translational analyses.

712 patients with primary invasive breast cancer will be randomized to either a supervised intervention of high-intensity interval and resistance training during NACT, supported by an exercise app, or to usual care, and followed for two years. Physical activity is meticulously tracked. By offering patients active involvement, the trial contributes strongly to the concept of personalized medicine.

Read the detailed description

The Neo-ACT assesses the primary endpoint pathological complete response (pCR) and the secondary endpoints Residual Cancer Burden (RCB), objective tumour response (RECIST), all-cause, breast cancer-specific, and recurrence-free survival at 2, 5 and 10 years, health-related quality of life assessed by the EORTC QLQ-C30 and BR23 questionnaires, self-reported physical activity (Modified Godin Leisure Time Physical activity questionnaire), toxicity-related outcomes (chemotherapy completion rates, number of unplanned hospital admissions during NACT, objective cognitive dysfunction (Amsterdam Cognition Scan), cardiac toxicity and sick leave), device-measured physical activity level (Fitbit activity tracker), muscle strength (handgrip strength test and hypothetical 1-RM maximal leg muscle strength tests), and cardiorespiratory fitness (Ekblom-Bak submaximal cycle test).

Participants randomized to the exercise group will complete 120 min exercise sessions per week from initiation of NACT to surgery (approx. five months):

  • Progressive home exercise program by an individualised mobile phone application, supported by local physiotherapists
  • Initial exercise intensity individually tailored to each patient's fitness at baseline and rate of perceived exertion during the program and adapted if required
  • Sessions will begin with a 3-minute moderate intensity (12-13 on Borg's Rate of Perceived Exertion (RPE) scale) warm-up.
03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with primary invasive breast cancer cT1-T3 cN0-2
  • Full tumour biology available before initiation of NACT
  • Oral and written consent
  • Age ≥ 18 years

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breast-feeding
  • Bilateral invasive breast cancer
  • The presence of musculoskeletal, neurological, respiratory, metabolic or cardiovascular conditions that may prevent safe completion of the exercise demands of the study
  • Currently performing equal to or more than 150 mins of moderate to high intensity aerobic exercise and 2 sessions per week of moderate intensity resistance exercise
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
712 participants (estimated)

Study arms

  • No intervention
    Standard

    Routine information on the benefit of physical activity

  • Experimental
    Intervention

    High-intensity interval and strength training during neoadjuvant chemotherapy

    Behavioral: Physical training

Interventions

  • BehavioralPhysical training

    Participants randomized to the exercise group will complete two structured 60-min exercise sessions per week from initiation of NACT to surgery (approx. five months).

06

What researchers measure

Primary outcomes

  1. Pathological complete response

    Absence of residual invasive tumor in breast and axilla at surgery

    Time frame: 5-6 months

Secondary outcomes

  1. Global health-related quality of life

    assessed by the EORTC QLQ-C30 questionnaire

    Time frame: baseline, after 1 and 2 years

  2. Breast cancer-related quality of life

    assessed by the EORTC QLQ-B23 questionnaire

    Time frame: baseline, after 1 and 2 years

  3. Self-reported physical activity

    Modified Godin Leisure Time Physical activity questionnaire

    Time frame: baseline, pre-surgery, 1- and 2-year follow-up

  4. Chemotherapy completion rate

    proportion of participants receiving the planned number of treatments

    Time frame: 1 year

  5. Cumulative chemotherapy dosage

    total dose of NACT received to account for potential dose reduction

    Time frame: 1 year

  6. Objective cognitive dysfunction

    online neuropsychological test (Amsterdam Cognition Scan)

    Time frame: baseline and 1 year

  7. Sick leave

    Patient-reported absence from work

    Time frame: pre-surgery and at 1- and 2-year follow-up

  8. Device-measured physical activity level

    Fit-bit tracker

    Time frame: baseline and 5-6months (pre surgery)

  9. Muscle strength

    hypothetical 1-RM maximal leg muscle strength test

    Time frame: baseline and 5-6 months

  10. Handgrip strength

    handgrip strength test

    Time frame: baseline and 5-6 months

  11. Cardiorespiratory fitness

    Åstrand submaximal cycle test

    Time frame: baseline and 5-6 months (pre-surgery)

  12. Radiological tumour response

    RECIST

    Time frame: 5-6 months

  13. Residual Cancer Burden (RCB)

    Degree of tumor response to NACT

    Time frame: 5-6 months

07

Study locations

9 of 13 sites recruiting
08

References and documents

Publications

  • de Boniface J, Altena R, Haddad Ringborg C, Bolam KA, Wengstrom Y. Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: Trial protocol of the randomized Neo-ACT trial. PLoS One. 2022 Oct 13;17(10):e0274804. doi: 10.1371/journal.pone.0274804. eCollection 2022. PubMed 36227931 ↗

Individual participant data

Plan to share: Yes — IPD will be available after study completion upon reasonable request submitted to the PI and with all legal and ethical requirements being fulfilled.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Study protocol, SAP and ICF available on trial homepage presently. Open access. CSR and analytic code available on request, see above.

Data sharing details ↗ · ki.se

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Dec 2027, 61 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 61 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2021
First posted
Jan 11, 2022
StartActual
Nov 9, 2022
Primary completionEst.
Dec 2027
CompletionEst.
Jun 2028
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05184582
Responsible party
Jana de Boniface (Ass. Prof, PI, Karolinska Institutet) — Principal investigator
First posted
Jan 11, 2022
Start date
Nov 9, 2022
Primary completion
Dec 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Sep 22, 2025

Study contacts

Jana de Boniface
Contact
jana.de-boniface@ki.se
+46702472305
Cecilia Haddad Ringborg
Contact
cecilia.haddad.ringborg@ki.se
Jana de Boniface
principal investigator · Karolinska Institutet

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion